HWM
BMRN icon

Hemington Wealth Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Hemington Wealth Management’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$9K Buy
169
+101
+149% +$5.78K ﹤0.01% 903
2025
Q2 		$3K Sell
68
-87
-56% -$5.12K ﹤0.01% 1213
2025
Q1 		$10K Buy
155
+82
+112% +$5.52K ﹤0.01% 807
2024
Q4 		$4K Sell
73
-3
-4% -$201 ﹤0.01% 1056
2024
Q3 		$5K Buy
+76
New +$6.35K ﹤0.01% 913

Other funds holding BMRN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Hemington Wealth Management's BMRN Position: Q3 2025 in Review

Hemington Wealth Management increased its BioMarin Pharmaceuticals (BMRN) stake by 149% in Q3 2025, buying an estimated $5.78K and bringing the position to 169 shares worth $9K. The position accounts for ﹤0.01% of the portfolio, ranked #903.

Hemington Wealth Management first reported a position in BMRN in Q3 2024 and has held it in 5 quarters since. The position peaked at $10K in Q1 2025. 576 funds tracked by Wall St. Rank hold BMRN as of Q3 2025.

  • Hemington Wealth Management held 169 shares of BioMarin Pharmaceuticals worth $9K as of Q3 2025.
  • Hemington Wealth Management bought 101 BioMarin Pharmaceuticals shares in Q3 2025, an estimated $5.78K.
  • BioMarin Pharmaceuticals made up ﹤0.01% of Hemington Wealth Management's portfolio in Q3 2025, its #903 holding.
  • Hemington Wealth Management first reported a position in BioMarin Pharmaceuticals in Q3 2024 and has held it in 5 quarters since.
  • Hemington Wealth Management's BioMarin Pharmaceuticals position peaked at $10K in Q1 2025.
  • 576 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2025.

Based on Hemington Wealth Management's 13F filing for Q3 2025, filed 24 Oct 2025.